European Growth Stocks With Strong Insider Ownership For August 2026
As the European markets navigate through global economic uncertainties, including inflationary pressures and geopolitical tensions, investors are increasingly looking towards growth stocks with strong insider ownership as a potential avenue for stability and long-term value. In this environment, companies where insiders hold significant stakes can signal confidence in their business models and alignment with shareholder interests, making them appealing candidates for those seeking resilient investment opportunities.
Top 10 Growth Companies With High Insider Ownership In Europe
| Name | Insider Ownership | Earnings Growth |
| MilDef Group (OM:MILDEF) | 10.3% | 30.9% |
| Kuros Biosciences (SWX:KURN) | 25.9% | 58.6% |
| KebNi (OM:KEBNI B) | 11.8% | 105.2% |
| Gold Road International (OB:GOLDR) | 35.9% | 86% |
| Envipco Holding (ENXTAM:ENVI) | 15.4% | 100.4% |
| CTT Systems (OM:CTT) | 17.4% | 55.3% |
| Clavister Holding AB (publ.) (OM:CLAV) | 20.5% | 60.7% |
| CD Projekt Red (WSE:CDR) | 35.2% | 39.6% |
| Bonesupport Holding (OM:BONEX) | 10.6% | 32.2% |
| Bergen Carbon Solutions (OB:BCS) | 11.9% | 52% |
We're going to check out a few of the best picks from our screener tool.
Moltiply Group (BIT:MOL)
Simply Wall St Growth Rating: ★★★★☆☆
Overview: Moltiply Group S.p.A. is a holding company in the financial services industry with operations in Italy, Germany, and internationally, and it has a market cap of €1.41 billion.
Operations: The company's revenue is primarily derived from the Mavriq Division, contributing €460.23 million, and Moltiply BPO&Tech, which accounts for €263.72 million.
Insider Ownership: 18.3%
Moltiply Group's earnings are projected to grow significantly at 28.84% annually, outpacing the Italian market's 10.2%. Despite this, revenue growth is expected to lag behind the market at 4.3% annually. The company faces financial challenges with high debt levels and declining profit margins from last year (8.8% to 5.4%). Analysts agree on a potential stock price increase of 44%, but recent insider trading activity is unavailable for further insights.
- Click here and access our complete growth analysis report to understand the dynamics of Moltiply Group.
- Insights from our recent valuation report point to the potential overvaluation of Moltiply Group shares in the market.
STIF Société anonyme (ENXTPA:ALSTI)
Simply Wall St Growth Rating: ★★★★★☆
Overview: STIF Société anonyme manufactures and sells components for the handling of bulk products in France, with a market cap of €249.58 million.
Operations: The company's revenue is derived from several segments: Handling Equipment (€19.60 million), Explosion Energy (BESS) (€41.40 million), US Distribution Segment (€4.40 million), Active Industry Explosion (€6.80 million), and Passive Industry Explosion (€16.60 million).
Insider Ownership: 11.6%
STIF Société anonyme is poised for substantial growth, with earnings anticipated to rise 21.26% annually, surpassing the French market's 12.9%. The stock trades at a significant discount of 50.7% below its estimated fair value, suggesting potential upside. Despite high debt levels and no recent insider trading insights, its return on equity is forecasted to be robust at 32.1% in three years, reflecting strong financial performance expectations amidst high-quality earnings.
- Click here to discover the nuances of STIF Société anonyme with our detailed analytical future growth report.
- The valuation report we've compiled suggests that STIF Société anonyme's current price could be quite moderate.
Redcare Pharmacy (XTRA:RDC)
Simply Wall St Growth Rating: ★★★★☆☆
Overview: Redcare Pharmacy NV operates an online pharmacy business across several European countries, including the Netherlands, Germany, and France, with a market cap of €1.30 billion.
Operations: The company's revenue segments consist of €2.63 billion from the DACH region and €583.90 million from international markets.
Insider Ownership: 11.9%
Redcare Pharmacy is forecasted to achieve profitability within three years, with earnings growth anticipated at 58.6% annually, outpacing the German market's revenue growth of 6.7%. Despite its volatile share price and recent net loss of €5.8 million for H1 2026, the stock trades significantly below its estimated fair value and expects a full-year revenue increase between 15% and 17%. However, substantial insider selling has been observed recently.
- Unlock comprehensive insights into our analysis of Redcare Pharmacy stock in this growth report.
- Our comprehensive valuation report raises the possibility that Redcare Pharmacy is priced higher than what may be justified by its financials.
Key Takeaways
- Click this link to deep-dive into the 213 companies within our Fast Growing European Companies With High Insider Ownership screener.
- Interested In Other Possibilities? We've found 7 US stocks that are forecast to pay a dividend yeild of over 6% next year. See the full list for free.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.The analysis only considers stock directly held by insiders. It does not include indirectly owned stock through other vehicles such as corporate and/or trust entities. All forecast revenue and earnings growth rates quoted are in terms of annualised (per annum) growth rates over 1-3 years.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com